Nicotine (Pyridine Alkaloid · nAChR Agonist · NRT · Informational Reference)
| Compound | Nicotine |
| Chemical class | Alkaloid — Pyridine (3-(1-Methylpyrrolidin-2-yl)pyridine) |
| CAS | 54-11-5 |
| Primary source | Nicotiana tabacum (tobacco leaves), Nicotiana rustica; trace in Solanum, Capsicum |
| Key applications | Nicotinic acetylcholine receptor agonist; cognitive enhancement; regulated NRT; addictive substance |
| Claim strength | High (NRT); controlled/restricted |
| Typical form | Pharmaceutical NRT (patches, gum, lozenges, inhalers); e-cigarette liquid; not a dietary supplement |
| Buy from Herbuno | Browse HerbIQ Compound Index → |
Name origin: From Nicotiana (the tobacco genus), named in honour of Jean Nicot de Villemain, the French ambassador who introduced tobacco to the French court in 1560. Nicotine is a pyrrolidine-pyridine bicyclic alkaloid and the primary psychoactive constituent of tobacco. Traditional use: Tobacco has been cultivated and used by indigenous peoples of the Americas for at least 2,000 years — for ceremonial, medicinal, and social purposes. European introduction of tobacco in the 16th century led to global adoption as a recreational substance, with nicotine addiction driving the largest preventable cause of death globally. Pharmacology: Nicotine is a full agonist at neuronal nicotinic acetylcholine receptors (nAChRs), particularly α4β2 and α7 subtypes. It produces short-term cognitive enhancement (attention, working memory) via ACh and dopamine release, but tolerance develops rapidly and withdrawal produces significant dysphoria — the basis of tobacco addiction. Chronic tobacco smoke exposure (not nicotine alone) causes cardiovascular disease and cancer; nicotine itself has cardiovascular risk at high doses. Nicotine replacement therapy (NRT): Pharmaceutical NRT preparations (patches, gum, lozenges, nasal spray, inhalers) are approved and recommended for smoking cessation — delivering nicotine without tobacco carcinogens to manage withdrawal symptoms. NRT represents some of the most robust public health evidence in medicine. Supplement/regulatory status: Nicotine cannot be sold as a dietary supplement in the US (FDA position since 2019) or as a food supplement in the EU. All commercial nicotine preparations are pharmaceutical or regulated consumer products.
Nicotine — Pharmacological and Clinical Context
Cognitive enhancement (acute): Nicotine at sub-addictive doses (2–4 mg transdermal) produces measurable improvements in sustained attention, working memory, and fine motor performance in healthy non-smokers in controlled studies. This “nootropic” effect is the basis for research interest in nicotine for Alzheimer’s, ADHD, and Parkinson’s disease (where nicotine was studied for neuroprotection). However, addiction potential and cardiovascular risk preclude supplement positioning. Claim strength: High (acute cognitive effects well-documented); supplement use is not appropriate.
Smoking cessation (NRT): Cochrane meta-analysis (Hartmann-Boyce et al. 2018, 136 RCTs, n=64,640) confirms NRT increases long-term smoking cessation rates by 50–60% versus placebo. Combined NRT (patch + short-acting form) is more effective than single NRT. NRT is recommended as first-line pharmacological support in all major smoking cessation guidelines. Claim strength: High (pharmaceutical context).
Parkinson’s disease neuroprotection: Epidemiological data show consistent inverse association between tobacco smoking and Parkinson’s disease risk (50% risk reduction in smokers). Nicotine’s α7-nAChR agonism promotes dopaminergic neuron survival. Multiple trials of transdermal nicotine for PD neuroprotection have shown cognitive improvements. This remains an active research area. Claim strength: Moderate (epidemiological + clinical trials; not approved for PD).
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Frequently Asked Questions — Nicotine
Is nicotine the cause of cancer from smoking?
No — nicotine is not the primary carcinogen in tobacco smoke. Cancer results from the over 70 known carcinogens in tobacco combustion products (NNK, PAHs, benzene, formaldehyde). Nicotine is primarily responsible for addiction, making smokers continue exposure to these carcinogens. Nicotine itself has pro-tumour effects in some cancer models (promoting angiogenesis and reducing apoptosis) but is not classified as a carcinogen by IARC. Long-term NRT use (without smoking) does not carry the cancer risk of tobacco smoking.
Why can’t nicotine be sold as a dietary supplement?
The FDA ruled in 2019 that nicotine cannot be marketed as a dietary supplement because it was first investigated and approved as a pharmaceutical drug (NRT) before being marketed as a supplement — the “drug preclusion” provision of DSHEA. The EU similarly regulates nicotine as a medicinal product. This creates a clear regulatory moat around nicotine — any nicotine-containing product must navigate the pharmaceutical pathway rather than the supplement pathway.
Are there natural low-nicotine alternatives with similar cognitive effects?
Cytisine (Laburnum alkaloid, also a nicotinic partial agonist) has been studied as a smoking cessation agent. Low-dose nicotine analogues from tomatoes, potatoes, peppers, and aubergine provide trace dietary nicotine at levels far below pharmacological thresholds. For nootropic positioning without nicotine’s regulatory and addiction concerns, the cholinergic pathway can be addressed via alpha-GPC, CDP-choline, or huperzine-A — all of which enhance cholinergic neurotransmission without nicotinic receptor direct agonism.
What is the difference between tobacco nicotine and synthetic nicotine?
Chemically identical — (S)-nicotine is the natural enantiomer from tobacco; synthetic nicotine produced by chemical synthesis has historically been a racemic mixture ((R+S)-nicotine), though enantioselective synthesis of (S)-nicotine is now commercially established. The FDA in 2022 ruled that synthetic nicotine in e-cigarettes also requires FDA review under the Tobacco Product Manufacturing Practice rules — closing the regulatory gap that some manufacturers had attempted to exploit.
Related compounds: Cytisine, Sparteine, Lobeline, Anabasine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery